
Neurofibromatosis is a complex medical condition. It describes the emergence of tumors that can impact the brain, spinal cord, and the nerves that transmit messages from the brain and spinal cord to every other area of the body. The majority of tumors are benign (non-cancerous), while some have the potential to develop into malignant tumors.
Most children with NF1 develop many skin spots by the time they become one year old; these patches are known as café-au-lait spots due to their color. Spots that are greater than 1/4 inch (5 millimeters) across and darker than the surrounding skin . Compared to ordinary children, children with NF1 may take longer to walk, talk, and reach other developmental milestones.
Additionally, they might have
Causes
A mutated gene that either develops during pregnancy or is inherited from a parent causes neurofibromatosis type 1. Chromosome 17 contains the NF1 gene. A protein termed neurofibromin, which is produced by this gene, aids in controlling cell division. Neurofibromin is lost as a result of gene alteration. This permits unchecked cell growth.
Risk Factors
A family history is the largest risk factor for neurofibromatosis type 1 (NF1). Approximately 50% of individuals with NF1 have a parent-inherited form of the disease. Individuals with NF1 who have unaffected relatives are likely to have a novel gene mutation.
The inheritance pattern for NF1 is autosomal dominant. This indicates that the mutated gene is 50% likely to be present in any child of a parent with the condition.
Complications
Even within the same family, neurofibromatosis type 1 (NF1) complications can differ. Complications usually arise when tumors strain on internal organs or damage nerve tissue.
The treatment of neurofibromas, especially those linked to Neurofibromatosis Type 1 (NF1), has improved in the United Arab Emirates because of a combination of cutting-edge medicines and contemporary diagnostics. Medical centres use comprehensive genetic testing to find particular mutations, which helps with individualised treatment regimens. Protein inhibitors are one type of emerging therapy that has demonstrated effectiveness in shrinking tumours and easing symptoms in people with neurofibromas that cannot be operated on. Clinical trials are also being conducted to assess the potential of innovative medications to provide safer and more efficient treatment alternatives.
Since neurofibromatosis is inherited, there are currently no recognized preventative measures.
Chemotherapy: In order to reduce neurofibromas and relieve a patient's symptoms, chemotherapy drugs function by eliminating cells that divide too quickly. The following chemotherapy medications may be recommended for neurofibromatosis: Vinblastine, carboplatin, methotrexate, ifosfamide, and doxorubicin. Since chemotherapy is systemic (treats the entire body rather than just one portion), it is frequently a good choice for treating neurofibromatosis. Chemotherapy may be a more effective alternative than focused treatments like radiation therapy since neurofibromatosis tumors can develop in numerous areas simultaneously.
Cost Start From USD 800 - USD 6000Explore Options
Radiation Therapy: Certain neurofibromatosis complications, including peripheral nerve sheath tumors (malignant tumors that develop in other parts of the body), acoustic neuromas (tumors that develop in the inner ears), and optic nerve gliomas (tumors that develop in the eyes), can be treated with radiation therapy. Although neurofibromas are noncancerous tumors that are typically left untreated unless they are extremely large or painful, they can occasionally be shrunk with radiation therapy.
A medical practitioner will first analyse a patient's personal and family medical history and do a physical examination in order to diagnose neurofibromatosis. In order to identify NF1, the patient's skin is examined for cafe au lait spots.
Additional tests include:
Although there is no cure for NF1, there are medicines that can help control its symptoms. A large number of NF1 patients won't need ongoing care. Some patients return home the same day of surgery, while others may need to stay in the hospital for one to three days, depending on the size and location of the neurofibromatosis. Rehab may be necessary for a full recovery, which could take six months.
Depending on the situation, your healthcare professional may prescribe medicine to help control your symptoms and support the treatment plan









Sharjah, United Arab Emirates
Zulekha Hospital Sharjah located in Sharjah, United Arab Emirates is accredited by ISO, JCI. Also listed below are some of the most prominent infrastructural details:

Abu Dhabi, United Arab Emirates
The Hospital owns an International Patient Services Team that is responsible to assist international patients with world-class healthcare, transportation arrangement, accommodation facilities, language interpreters, and much more.
Burjeel Medical City (about 1.2 million square facilities)provides 7-star hospitality to its patients. It has the largest facility space bed among all the private hospitals. The Hospital consists of-

Dubai, United Arab Emirates
Zulekha Hospital Dubai located in Dubai, United Arab Emirates is accredited by ISO, JCI. Also listed below are some of the most prominent infrastructural details:
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Here are some of the reasons for choosing UAE:
There is currently no treatment that can cause the majority of neurofibromatosis to recede or go away, and the only option to get rid of them once they have grown is through surgery. For children aged two and older with NF1 who have plexiform neurofibromatosis that produces symptoms and cannot be surgically removed, the Food and Drug Administration has approved the oral drug selumetinib. A malignant plexiform neurofibroma may require chemotherapy and radiation treatment.
In UAE, neurofibromatosis is effectively treated with minimally invasive surgical procedures, targeted medication therapy such as protein inhibitors, and sophisticated genetic testing. For improved disease management, a multidisciplinary approach guarantees thorough and individualised treatment.
Yes, many UAE hospitals offer the following for neurofibromatosis treatment:
Always consider the following factors when selecting a hospital in the UAE:
With the use of tailored medication therapy, minimally invasive surgeries, and sophisticated genetic tests, neurofibromatosis treatment in the UAE has a high success rate.
You must look for any lumps or rubbery bumps on the baby's skin and determine whether the baby is itching. A concerned physician should do a physical examination and other tests to confirm the diagnosis.
Over time, neurofibromatosis, particularly plexiform, can enlarge and press against nerves and organs, resulting in pain, weakness, or impaired function. It can result in bone deformities including scoliosis, neurological problems like eyesight or hearing loss, and malignant peripheral nerve sheath tumours (MPNSTS). Skin spots may affect one's sense of self-worth and social confidence, and the condition also raises the risk of heart issues and high blood pressure.
No, we cannot cure neurofibromatosis before birth.
Here are some ways you can take care of your child:
The majority of kids with neurofibromatosis lead everyday, whole lives with only minor symptoms. A child with neurofibromatosis requires routine examinations so that medical professionals can screen for:
You can see the top neuro hospitals and doctors in the UAE for a second opinion on Neurofibromatosis treatment. Numerous prestigious medical facilities consult with skilled doctors who will examine your diagnosis and suggest the best course of action. You can get support by speaking with a medical tourism facilitator at MediGence to select the best doctor and facility. It provides specialised rehabilitation programs.